Daewoong's 'DW-MSC' exosome extraction, purification and joint development of new indications
Daewoong Pharmaceutical will join hands with an exosome treatment company to expand the field of new drug development.
Daewoong Pharmaceutical announced on the 6th that it had signed an agreement with Exostemtech to jointly develop a stem cell-derived exosome treatment at its Samsung-dong headquarters on the 5th.
According to this agreement, the two companies will establish a technology for extracting and purifying exosomes from stem cells of Daewoong Pharmaceutical's 'DW-MSC' and jointly develop exosome treatment expansion research and new indications. Exostemtech's pipeline clinical joint development cooperation and technology transfer are also possible.